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Tools for Genetic and Genomic Studies in
Emerging Model Organisms 
This Program Announcement (PA) is to encourage
investigator-initiated applications for research
designed to generate genetic tools and genomic
resources that will enable researchers to exploit the
full potential of novel or developing model systems
for comparative and functional genomic studies. The
typical model organism to be considered should have
a publicly available draft of the genomic DNA
sequence with a minimum of 5X coverage. In addi-
tion, it should have at least one of the following
characteristics: shows promise as, or is, a model for
basic biological or behavioral mechanisms; occupies
an important evolutionary niche that may yield
novel insights in comparative studies; or has poten-
tial as, or is, a model for developmental or disease
processes. Applicants are expected to ensure that
reagents, technologies, and resources developed
under this initiative are made widely available to the
research community.
This PA is not intended to encourage genome
sequencing projects or studies of model organisms for
which there are well-established databases and other
genome-related resources, e.g, mouse, Drosophila, C.
elegans, and S. cerevisiae. In general, resources to study
organisms that fit primarily within the mission of
another National Institutes of Health (NIH) Institute
or Center, such as pathogenic microorganisms, are not
encouraged through this PA.
The advent of the genomic era has been a boon
for the investigation of a growing number of model
organisms. Completion of DNA sequencing of each
genome presents opportunities for novel insights into
genomic function, the regulation of gene expression,
and evolutionary processes. Yet, the large scale of
many sequencing projects and the sheer volume of
sequence data create a considerable challenge for the
individual investigator as well as consortia of
researchers to obtain the resources and tools required
to make maximal use of genomic information for
comparative or functional studies.
The major goal of this PA is to support research
that will enhance the usefulness of DNA sequence
information for newly emerging or developing model
organisms for which there are limited genomic
resources. Objectives to be addressed in applications
submitted in response to this PA include, but are not
limited to, the following: 1) improvements in tools
for mining of data for genomes having unique com-
position or structure; 2) improved database manage-
ment and integration with other databases (requests
for the maintenance of databases alone are not
encouraged); 3) generation of comprehensive cDNA
libraries; 4) development of microarray reagents
and/or services; 5) improved methods for linking
expression arrays with standard phenotypes or with
speciﬁc biological or behavioral outcomes; 6) devel-
opment of novel approaches for mutagenesis and for
rapid identification and characterization of point
mutations; 7) development of novel transposable ele-
ment-based techniques for the generation of knock-
outs or other mutations; 8)improvements in gene
transfer technology and in vectors for genomic
manipulation; and 9) generation of sets of gene
knockouts or knock-downs.
This PA will use the NIH research resource grant
(R24) mechanism. Responsibility for the planning,
direction, and execution of the proposed project will
be solely that of the applicant. The total project period
for an application submitted in response to this PA
may not exceed four years. A maximum of $250,000
direct costs (exclusive of subcontractual indirect costs)
per year will be provided.
This PA uses just-in-time concepts. It uses the
non-modular budgeting format. Follow the instruc-
tions for non-modular budget research grant applica-
tions. This program does not require cost sharing as
deﬁned in the current NIH Grants Policy Statement
at http://grants.nih.gov/grants/policy/nihgps_2003/
NIHGPS_Part2.htm.
The NIH is interested in ensuring that the
research resources (constructs, reagents, cell lines,
software tools, expression data, methods, etc.) devel-
oped through this PA become readily available to the
research community for further research, develop-
ment, and application, in the expectation that this
will lead to products and knowledge of beneﬁt to the
public. At the same time, NIH recognizes the rights
of grantees to elect and retain title to subject inven-
tions developed under federal funding under the pro-
vision of the Bayh-Dole Act.
This PA has two special requirements regarding
research resources produced in proposed projects:
1) Applicants are required to include in their applica-
tions a speciﬁc plan by which they will share research
resources with the wider scientiﬁc community. A rea-
sonable time frame for periodic deposition of
mutants, reagents, and data should be speciﬁed in the
application. 2) Applicants are required to include a
plan addressing if, or how, they will exercise their
intellectual property rights while making available to
the broader scientiﬁc community patentable research
resources. The plan should address the following
questions: Will material transfers be made with no
more restrictive terms than in the Simple Letter
Material Transfer Agreement or the Uniform
Biological Material Transfer Agreement? Will there
be reach-through requirements on materials trans-
ferred? Should any intellectual property arise that
requires a patent, will the technology remain widely
available to the research community?
Both the sharing and intellectual property plans
should, at a minimum, address these elements in a
clear and concise manner. Applicants are encouraged
to inform and/or confer with their institutional
offices of technology transfer to develop plans for
addressing these requirements. 
Applicants are reminded that the grantee institu-
tion is required to disclose each subject invention to
NIH within two months after the inventor discloses
it in writing to grantee institutional personnel respon-
sible for patent matters. The awarding Institute
reserves the right to monitor awardee activity in this
area to ascertain if patents or patent applications are
adversely affecting the goals of this PA.
Applications must be prepared using the PHS
398 research grant application instructions and forms
(rev. 5/2001). Applications must have a Dun and
Bradstreet (D&B) Data Universal Numbering System
(DUNS) number as the Universal Identifier when
applying for federal grants or cooperative agreements.
The DUNS number can be obtained by calling 866-
705-5711 or through the web site at http://www.
dunandbradstreet.com/. The DUNS number should
be entered on line 11 of the face page of the PHS 398
form. The PHS 398 is available at
http://grants.nih.gov/grants/funding/phs398/
phs398.html in an interactive format. For further
assistance contact GrantsInfo, 301-435-0714, e-mail:
GrantsInfo@nih.gov. The title and number of this PA
must be typed on line two of the face page of the
application form and the YES box must be checked.
In the background section, the applicant should
include a description of existing publicly available
resources for the model organism being studied. The
applicant should define how the proposal will
enhance available resources and provide evidence of
research community consultation and consensus
regarding the potential value of the resource. In a
brief section following the research plan, the appli-
cant must describe plans to share research resources
and to exercise intellectual property rights 
Applications submitted in response to this PA
will be accepted at the standard application deadlines,
which are available at http://grants.nih.gov/
grants/dates.htm. Application deadlines are also indi-
cated in the PHS 398 application kit.
Submit a signed, typewritten original of the
application, including the checklist, and ﬁve signed
photocopies in one package to: Center for Scientiﬁc
Review (CSR), NIH, 6701 Rockledge Drive, Room
1040, MSC 7710, Bethesda, MD 20892-7710 USA;
Bethesda, MD 20817 (for express/courier service).
Applications must be mailed on or before the
receipt dates described at http://grants.nih.gov/
grants/funding/submissionschedule.htm. The CSR
will not accept any application in response to this PA
that is essentially the same as one currently pending
initial review unless the applicant withdraws the
pending application. The CSR will not accept any
application that is essentially the same as one already
reviewed. This does not preclude the submission of a
substantial revision of an unfunded version of an
application already reviewed, but such application
must include an introduction addressing the previous
critique.
Contact: Anthony Carter, Division of Genetics
and Developmental Biology, National Institute of
General Medical Sciences (NIGMS), Building 45,
Room 2AS-25R, MSC 6200, Bethesda, MD 20892-
6200 USA, 301-594-0943, fax: 301-480-2228,
e-mail: CarterA@nigms.nih.gov.
Reference: PA No. PA-04-141
NLM Research Grants in Biomedical Informatics
and Bioinformatics (R01)
The purpose of this PA is to reissue and update the
National Library of Medicine’s (NLM) research grant
program for biomedical informatics and bioinformat-
ics. NLM’s research funding centers on understand-
ing data, information and knowledge, in particular
their nature, forms and uses in the domains of health
care and basic biological sciences.
NLM defines biomedical informatics as the
intersection of basic informational and computing
sciences with an application domain in biomedicine,
as discussed in the work of the American College of
Medical Informatics referenced below. The term bio-
medical informatics encompasses the closely-aligned
ﬁeld of bioinformatics, which can be deﬁned as the
intersection of basic informational and computer sci-
ences with an application domain in biological/bio-
chemical sciences. NLM’s research focuses on
management and efﬁcient utilization of data, infor-
mation, and knowledge in health care and basic bio-
medical sciences. 
In clinical medicine, health services administra-
tion, education, and basic biomedical sciences, com-
puters and networks are fundamental tools of
discovery, learning, decision making and management.
NLM’s biomedical informatics research grants support
the study of how information is best captured, repre-
sented, stored, retrieved, manipulated, managed and
disseminated for use in these kinds of activities.
The following general themes demonstrate the
range and scope of NLM’s research interests in bio-
medical informatics and bioinformatics: 1) informa-
tion and knowledge processing, including natural
language processing, information extraction, integra-
tion of data from heterogeneous sources or domains,
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lyzing and/or storing very large datasets, including
genomic and proteomic data, data supporting clini-
cal trials, and other data used in clinical or health ser-
vices research; 3) knowledge representation,
including vocabularies, ontologies, simulations and
virtual reality; 4) linkage of clinical and genomic
information to beneﬁt health care; 5) innovative uses
of information technology in health care delivery,
including decision support, error reduction, out-
comes analysis, and information at the point of care;
6) efﬁcient management and utilization of informa-
tion and data, including knowledge acquisition and
management, process modeling, data mining, acqui-
sition and dissemination, novel visual presentations,
and stewardship of large-scale data repositories and
archives; 7) human-machine interaction, including
interface design, use and understanding of health
related-information, intelligent agents, information
needs and uses. 8) high-performance computing and
communications relating to biomedical applications,
including efficient machine-machine interfaces,
transmission and storage, and real-time decision sup-
port; 9) innovative uses of information technology to
enhance learning, retention and understanding of
health-related information.
Informatics research is interdisciplinary and
employs a range of research methodologies. NLM
expects that investigators will employ sound tech-
niques that lead to the collection and analysis of
empirical evidence. These techniques may include
quantitative and/or qualitative approaches, including
laboratory and ﬁeld studies, surveys and needs analy-
ses, ’in silico’ experiments, modeling and simulation
studies. 
NLM is a participant in the National Institutes
of Health (NIH) Roadmap initiatives, many of which
include biomedical computing and interdisciplinary
research as essential elements, in the programs of the
NIH BISTI initiative, and other NIH informatics
initiatives. 
While biomedical informatics research projects
funded by this program often require software develop-
ment and tool-building, a well-deﬁned research prob-
lem and rigorous research design are essential elements
of NLM’s R01 grants. Investigators interested in
demonstration projects, proofs of concept or other fea-
sibility testing should consider NLM’s Exploratory/
Developmental grant program (http://grants.
nih.gov/grants/guide/pa-ﬁles/PA-03-107.html) rather
than this biomedical informatics research grant pro-
gram. NLM’s Small Project grants (http://grants.
nih.gov/grants/guide/pa-files/PA-03-108.html) are
most appropriate for investigators who are just begin-
ning their research in an area and/or need preliminary
data to inform a more substantial research project.
Research in biomedical informatics or bioinfor-
matics often employs a speciﬁc scientiﬁc discipline or
medical subspecialty as the subject ﬁeld or domain in
which the research is undertaken, or in which tools
and ideas are applied. However, grant applications
whose primary focus is on a disease or biological
question, rather than the informatics or computa-
tional issues that pertain to them, are more appropri-
ate for other Institutes at NIH.
This PA will use the NIH R01 award mecha-
nism. As an applicant, you will be solely responsible
for planning, directing, and executing the proposed
project. 
This PA uses just-in-time concepts. It also uses
the modular budgeting as well as the non-modular
budgeting formats (see http://grants.nih.gov/
grants/funding/modular/modular.htm). Speciﬁcally,
if you are submitting an application with direct costs
in each year of $250,000 or less, use the modular
budget format. Otherwise follow the instructions for
non-modular budget research grant applications. This
program does not require cost sharing as deﬁned in
the current NIH Grants Policy Statement at http://
grants.nih.gov/grants/policy/nihgps_2003/
NIHGPS_Part2.htm.
An applicant can request funding for up to ﬁve
years of support. The average duration of recent NLM
informatics research awards is about three years. 
Applications must be prepared using the PHS
398 research grant application instructions and forms
(rev. 5/2001). Applications must have a Dun and
Bradstreet (D&B) Data Universal Numbering System
(DUNS) number as the Universal Identifier when
applying for federal grants or cooperative agreements.
The D&B number can be obtained by calling 866-
705-5711 or through the web site at http://
www.dunandbradstreet.com/. The D&B number
should be entered on line 11 of the face page of the
PHS 398 form. The PHS 398 is available at http://
grants.nih.gov/grants/funding/phs398/phs398.html in
an interactive format. For further assistance contact
GrantsInfo, 301-435-0714, e-mail: GrantsInfo@
nih.gov. The title and number of this PA must be
typed on line two of the face page of the application
form and the YES box must be checked.
Applications submitted in response to this PA
will be accepted at the standard application deadlines,
which are available at http://grants.nih.gov/
grants/dates.htm. Application deadlines are also indi-
cated in the PHS 398 application kit. 
Submit a signed, typewritten original of the
application, including the checklist, and ﬁve signed
photocopies in one package to: Center for Scientiﬁc
Review, NIH, 6701 Rockledge Drive, Room 1040,
MSC 7710, Bethesda, MD 20892-7710 USA;
Bethesda, MD 20817 (for express/courier service).
Applications must be mailed on or before the
receipt dates described at http://grants.nih.gov/
grants/funding/submissionschedule.htm. The CSR
will not accept any application in response to this PA
that is essentially the same as one currently pending
initial review unless the applicant withdraws the
pending application. The CSR will not accept any
application that is essentially the same as one already
reviewed. This does not preclude the submission of a
substantial revision of an unfunded version of an
application already reviewed, but such application
must include an introduction addressing the previous
critique.
Contact: Valerie Florance, Deputy Director,
Extramural Programs Division, National Library of
Medicine, Rockledge 1, Suite 301, 6705 Rockledge
Drive, Bethesda, MD 20892-0001 USA, 301-594-
4882, fax: 301-402-2952, e-mail: floranv@
mail.nih.gov; Hua-Chuan Sim, Scientific Review
Administrator, Extramural Programs Division,
National Library of Medicine, Rockledge 1, Suite 301,
6705 Rockledge Drive , Bethesda, MD 20892-0001
USA, 301-496-4253, fax: 301-402-2952, e-mail:
simh@mail.nih.gov
Reference: PA No. 04-141
Quick-Trials for Novel Cancer Therapies:
Exploratory Grants
Continuing progress in basic cancer research and
drug development has led to discoveries of new
agents or approaches for molecular targeting in novel
cancer therapies. These new agents or approaches
suppress tumor growth through multiple mechanisms
such as cell cycle control, activation of tumor sup-
pressor genes, essential signal pathway blockage,
tumor vaccines, tumor microenvironment modiﬁca-
tion, etc. Rapid translation of these exciting discover-
ies into clinical practice requires timely support to
accommodate the special needs of novel cancer ther-
apy development. This Program Announcement
(PA) is intended to provide investigators with rapid
access to support for pilot, Phase I, and Phase II can-
cer clinical trials as well as support for patient moni-
toring and laboratory studies linked to a cancer
clinical trial. Phase III trials are not excluded but such
trials generally require greater resources and duration
than available from an R21 award. Applications that
do not propose a cancer clinical trial or patient moni-
toring or laboratory studies linked to a cancer clinical
trial may be returned to applicants without being
reviewed. The focus of this Quick-Trial PA is on
translational research in new agent development to
ensure the timely exploitation of new cancer thera-
peutic approaches including the development of new
cancer prevention agents. This PA is aimed at provid-
ing a new approach in the grant application process
by offering a rapid turnaround from application sub-
mission to funding. Features of this initiative include
a modular grant application and award process, inclu-
sion of the clinical protocol within the grant applica-
tion, and an accelerated peer review with the goal of
issuing new awards within six months of application
receipt. Inclusion of the complete clinical protocol
within the PHS 398 grant application is intended to
simplify the application process by eliminating the
need to duplicate protocol details in the Research
Plan section and to insure proper peer review of the
application. In addition, Quick-Trial applications do
not require extensive preliminary data in the grant
application and support exploratory translational and
clinical research studies involving cancer prevention,
chemotherapy and rapid development and applica-
tion of novel clinical cancer therapies including image
guided therapeutic procedures. Investigators may
apply for a maximum of two years of funding support
using the exploratory or developmental (R21) grant
mechanism for up to $250,000 direct costs per year.
Advances in the understanding of molecular can-
cer genetics, basic cancer biology, and the develop-
ment of powerful technologies such as microarray,
proteomics and bioinformatics have led to the identi-
ﬁcation of many new molecular targets and pathways
in cancer cells. These discoveries have created new
frontiers for novel molecular cancer prevention and
treatment leading to the development of molecular
medicine in cancer therapy. In addition, these novel
targets and pathways have presented excellent transla-
tional research opportunities for revolutionizing can-
cer drug development and bringing more effective
molecular cancer therapies and cancer prevention
strategies into clinical practice.
Novel approaches or agents for inhibiting tumor
growth either directly or by impacting the tumor
microenvironment are ready to be tested in the clinic
with new tools and laboratory analyses that allow
investigators to ascertain how specific targets are
affected by therapy. These agents include new classes
of cytotoxic agents, agents or approaches that act via
immune-stimulatory effects, agents that stimulate
apoptosis, inhibit angiogenesis and metastasis or alter
tumor cell signaling pathways, and agents targeted
speciﬁcally to novel cancer cell targets. New clinical
therapeutic trials may employ drugs/agents, biologics,
radiation, heat, or surgery used as single agents/modal-
ities or in combination for the treatment of early and
advanced disease. In addition, clinical trials of thera-
pies for cancer treatment, including but not limited to
herbal therapies, dietary supplements, bioactive food
components, or unconventional pharmacological and
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toxin, enzyme therapies, etc.) will be considered.
Another relevant area of investigation is the use of
anatomical and molecular image guidance for targeted
treatment with ablative techniques or delivery of
chemotherapeutic agents. At present, there are few
funding mechanisms targeted to stimulate the transla-
tion of promising and potentially relevant advances in
new prevention or therapeutic agent development
from the laboratory into the clinical setting. Quite fre-
quently the initial stages of clinical investigation are
the most difﬁcult to accomplish. They are resource
intensive, and, to be done well, they require labora-
tory, pharmacology, and other resource support, as
well as substantial personnel effort, none of which is
supported by traditional health benefit programs.
Nonetheless, these early studies tend to fare poorly in
competition for conventional grant support precisely
because they are preliminary and cannot serve as the
deﬁnitive tests of new approaches. Even when funding
is received, the review and award cycle may introduce
a year or more of delay. Except where there is an
industrial sponsor with a particular commitment to
development of an agent, it may take a long time for a
promising approach to get through the initial phase of
demonstrating feasibility and interest, or it may never
be tested in more than one or two diseases.
This PA will continue to support scientiﬁc, tech-
nological, clinical and logistical needs in novel cancer
therapy development. In addition, this PA will com-
plement the Rapid Access to Intervention
Development (RAID) program http://dtp.nci.
nih.gov/docs/raid/raid_index.html by providing an
initiative with accelerated peer review and funding to
support the clinical and laboratory costs of early clini-
cal testing to ensure the timely development of new
therapeutic approaches. 
This PA will use the NIH exploratory/develop-
ment (R21) award mechanism. As an applicant, you
will be solely responsible for planning, directing, and
executing the proposed project. The applicant may
request a project period of up to 2 years with direct
costs limited to $250,000 per year.
This PA uses just-in-time concepts. It also uses
the modular budgeting format (see http://grants.
nih.gov/grants/funding/modular/modular.htm). This
program does not require cost sharing as deﬁned in
the current NIH Grants Policy Statement at
http://grants.nih.gov/grants/policy/nihgps_2003/
NIHGPS_Part2.htm.
Applications must be prepared using the PHS
398 research grant application instructions and forms
(rev. 5/2001). Applications must have a Dun and
Bradstreet (D&B) Data Universal Numbering
System (DUNS) number as the Universal Identiﬁer
when applying for federal grants or cooperative agree-
ments. The D&B number can be obtained by calling
866-705-5711 or through the web site at http://
www.dunandbradstreet.com/. The D&B number
should be entered on line 11 of the face page of the
PHS 398 form. The PHS 398 document is available
at http://grants.nih.gov/grants/funding/phs398/
phs398.html in an interactive format. For further
assistance, contact GrantsInfo, 301-435-0714, e-
mail: GrantsInfo@nih.gov. The title and number of
this PA must be typed on line 2 of the face page of
the application form and the YES box must be
checked.
Because Quick-Trial applications will propose
cancer clinical trials or patient monitoring or labora-
tory studies linked to a cancer clinical trial, applicants
are reminded to properly complete item e (Humans
Subjects Research) of the Research Plan. This is
described in PHS 398. As applicable, the Human
Subjects Research portion of the Research Plan
includes, but is not limited to, a Data and Safety
Monitoring Plan, Women, Minority, and Children
Inclusion sections, and a Targeted/Planned
Enrollment Table.
Submit a signed, typewritten original of the
application, including the checklist, and ﬁve signed
photocopies in one package to: Center for Scientiﬁc
Review, National Institutes of Health, 6701
Rockledge Drive, Room 1040, MSC 7710, Bethesda,
MD 20892-7710 USA; Bethesda, MD 20817 (for
express/courier service).
The CSR will not accept any application in
response to this PA that is essentially the same as one
currently pending initial review unless the applicant
withdraws the pending application. The CSR will not
accept any application that is essentially the same as
one already reviewed. This does not preclude the sub-
mission of a substantial revision of an unfunded ver-
sion of an application already reviewed, but such
application must include an introduction addressing
the previous critique.
Contact: Roy Wu, Clinical Grants and
Contracts Branch, Cancer Therapy Evaluation
Program, Division of Cancer Treatment and
Diagnosis, National Cancer Institute (NCI), 6130
Executive Boulevard, EPN Room 7009, Bethesda,
MD 20892-7432 USA; Rockville, MD 20852 (for
express/courier service), 301-496-8866, fax: 301-480-
4663, e-mail: wur@ctep.nci.nih.gov 
Reference: PA No. PAR-04-155
Genetics and Pathobiology of Vascular Cognitive
Impairment
The purpose of this Program Announcement with
set-aside funds (PAS) is to invite applications to study
the biological basis of vascular cognitive impairment
(VCI). VCI causes a burden of illness similar to that
caused by Alzheimer’s disease (AD), but has been far
less well-studied. Recently, however, some important
strides have been made in understanding the etiology
of VCI. These include the discovery of a monogenic
form of vascular dementia, CADASIL, and identiﬁca-
tion of the causative gene as Notch 3. In addition,
MRI and other pathological data have provided a
clearer delineation of the various clinical subtypes of
VCI, and awareness of the synergistic interaction
between vascular and classical Alzheimer’s pathologies
in producing cognitive impairment. The goal of this
PAS is to build on these ﬁrst critical achievements to
obtain a better understanding of the cellular and mol-
ecular mechanisms causing vascular, neural, and glial
dysfunction in human VCI and animal models
of VCI.
The number of people affected by dementia in
the US is expected to increase three-fold in the next
50 years, to a total of over 13 million. The best-
known form of dementia is AD, whose definitive
diagnostic sign is the presence of plaques and tangles
in brain neurons upon autopsy. However, a large pro-
portion of dementia cases in the aged population are
not due to AD, but rather to cerebrovascular disease.
Dementia due to cerebrovascular disease is referred to
as “vascular dementia”, and can occur in the absence
of Alzheimer’s pathology. In addition to this so-called
“pure” vascular dementia, there are also cases of
“mixed” dementia in which cerebrovascular and
Alzheimer’s pathologies coexist. Recent studies sug-
gest that pure vascular dementia and mixed dementia
together comprise the majority of dementia cases in
some populations.
Vascular dementia can arise from any of several
cerebrovascular disease conditions, but its two major
causes are focal ischemic infarcts (i.e., strokes) and
subcortical ischemic vascular disease. Focal ischemic
infarcts result from occlusion of large vessels, in either
cortical or subcortical locations, and are accompanied
by acute clinical signs of neurological impairment.
(Dementia arising from large infarcts is also some-
times referred to as “multi-infarct dementia”.)
Subcortical ischemic vascular disease, on the other
hand, results from occlusion of small vessels, and cre-
ates widespread small lesions (lacunae) and/or areas of
demyelination. The areas affected are generally sub-
cortical, including the basal ganglia, cerebral white
matter and brainstem. This form of vascular disease
generally does not produce sudden, acute symptoms,
but rather causes longer-term, insidious changes in
neurological function. In a significant portion of
cases, this disease can even remain clinically silent for
the life of the individual. Subcortical small vessel dis-
ease can be diagnosed by imaging even in cases where
it is clinically silent.
In recent years, the term “vascular dementia” has
been replaced by the term “vascular cognitive impair-
ment (VCI)”. This change reﬂects the realization that
cerebrovascular disease can cause signiﬁcant cognitive
and functional decline in the absence of dementia as
defined by standard criteria. In addition, there is
increasing evidence that VCI differs from AD in terms
of precise range of cognitive defects associated with
each disease. AD is characterized primarily by episodic
memory loss due to loss of cholinergic basal forebrain
neurons and their projections to the hippocampus. In
contrast, VCI in its purest forms seems to be charac-
terized more by loss of executive function and atten-
tional mechanisms associated with prefrontal circuitry.
However, the spectrums of defects seen in VCI and
AD overlap substantially. This fact, together with the
frequent coexistence of vascular and Alzheimer’s
pathologies within individual patients, renders it difﬁ-
cult to provide deﬁnitive diagnoses based strictly on
cognitive tests.
Despite the enormous prevalence of VCI, the
biological basis of this disease has been much less well
studied than that of AD. This lack has been due in
part to the clinical heterogeneity of the disease, and
also to poor understanding of its pathology at the cel-
lular level. Recently however, research in VCI has
taken some critical ﬁrst steps forward. A genetic form
of vascular dementia, CADASIL, has been discov-
ered, and the mutant gene identified as Notch 3.
Previous research in animal models had shown Notch
3 to be important in early neural and vascular devel-
opment. The ﬁnding that mutation of Notch 3 leads
to stroke and dementia (both seen in CADASIL) sug-
gests that the gene also plays an important role in the
function or maintenance of vascular and/or neural
cells in the adult. Consistent with this possibility, a
transgenic mouse carrying the mutant form of Notch
3 has now been generated which shows degeneration
of smooth muscle cells similar to that seen in human
patients. These findings provide an important
foothold for understanding the cell biology as well as
the genetics of VCI. Moreover, the known interac-
tion of Notch with the presenilin proteins suggests a
juncture in the disease pathways underlying VCI and
AD, which also could be further explored in mouse
models.
Another major area ripe for exploration concerns
the genes and other risk factors that link vascular
pathology to neural pathology or that render individu-
als susceptible to neuronal damage and cognitive
impairment in response to cerebrovascular disease.
Some progress has been made in recent years in deﬁn-
ing genes that predispose individuals to stroke and
cerebrovascular disease per se, but no studies have yet
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to recover from ischemic injury. Identifying such
genes would provide clear paths both to understand-
ing the cell biology of VCI, and also to the design of
protective agents and therapeutics.
Research areas appropriate for this PAS would
include, but are not imited by the following exam-
ples: 1) genetics of VCI, in both animal models and
humans, in particular, identification of genes that
render individuals susceptible to cognitive impair-
ment secondary to cerebrovascular disease; 2) analysis
of cellular and molecular changes occurring in vascu-
lar, neuronal, and glial cells during the development
of VCI in human patients, and correlation of these
with MRI signs and changes in cognitive function; 3)
studies of cellular and molecular pathological
processes occurring in vascular, neuronal, and glial
cells in animal models of VCI, such as mouse lines
carrying mutant forms of Notch 3 or the stroke-
prone spontaneously hypertensive rat; 4) studies of
Notch 3 function in the maintenance and repair of
vascular, neuronal, and glial cells in normal adult ani-
mals; studies of the cellular and molecular bases of the
pathogenic actions of mutant Notch 3; 5) studies of
the cellular and molecular bases of the interaction
between the VCI and AD pathways (for example,
studies of vascular function and pathology in animal
models of AD); 6) development and characterization
of new animal models for the study of VCI, and of
the interaction between VCI and AD pathogenic
mechanisms; 7) analysis of cognitive function in ani-
mal models of VCI, and correlation of changes in
cognitive function with cellular and molecular
pathologies; 8) studies on the cellular and molecular
effects of hypertension, diabetes, hyperlipidemia,
coagulant and anticoagulant proteins, inﬂammatory
cytokines, and complement proteins on the vessel
wall in appropriate animal models for VCI.
This PAS will use the NIH R01 and R21 award
mechanism(s). As an applicant, you will be solely
responsible for planning, directing, and executing the
proposed project. The proposed project period dur-
ing which the research will be conducted should ade-
quately reﬂect the time required to accomplish the
stated goals The R21 mechanism (see http://
grants.nih.gov/grants/guide/pa-ﬁles/PA-03-107.html)
is intended to encourage exploratory and develop-
mental research projects by providing support for the
early and conceptual stages of these projects. These
one-time awards support innovative, high impact
research projects that assess the feasibility of a novel
area of investigation or a new experimental system,
include the unique and innovative use of an existing
methodology to explore a new scientiﬁc area, involve
considerable risk but may lead to a breakthrough in a
particular area, or develop new technology or
methodology that could have major impact in a spe-
cific research area. Applications for R21 awards
should describe projects distinct from those sup-
ported through the traditional R01 mechanism. For
example, long-term projects, or projects designed to
increase knowledge in a well-established area will not
be considered for R21 awards. Applications submit-
ted under this mechanism should be exploratory and
novel. These studies should break new ground or
extend previous discoveries toward new directions or
applications.
R21 applications may request a project period of
up to two years with a combined budget for direct
costs of up to $275,000 for the two year period. For
example, you may request $100,000 in the ﬁrst year
and $175,000 in the second year. The request should
be tailored to the needs of your project. Normally, no
more than $200,000 may be requested in any single
year. For further information on the R21 mechanism,
including Institute-specific information, see
http://grants.nih.gov/grants/guide/pa-files/PA-03-
107.html.
This PAS uses just-in-time concepts. It also uses
the modular budgeting as well as the non-modular
budgeting formats (see http://grants.nih.gov/
grants/funding/modular/modular.htm). Speciﬁcally,
if you are submitting an application with direct costs
in each year of $250,000 or less, use the modular
budget format. Otherwise follow the instructions for
non-modular budget research grant applications.
The National Institute of Neurological
Disorders and Stroke (NINDS) has set aside a total
of $2,250,000, in addition to funds available for
applications sent in response to this PA that score
within the NINDS payline (see NINDS Funding
Strategy http://www.ninds.nih.gov/funding/
ninds_funding_strategy.htm), depending on the
overall scientific merit of the applications and the
availability of funds throughout the duration of this
solicitation (three years). The National Institute on
Aging (NIA) has set aside a total of $300,000, and
the National Heart, Lung and Blood Institute
(NHLBI) has set aside a total of $350,000.
PHS policy requires that investigators make
unique research resources available for research pur-
poses to qualiﬁed individuals within the scientiﬁc com-
munity when they have been published (see the NIH
Grants Policy Statement at http://grants.nih.gov/
grants/guide/notice-ﬁles/not96-184.html). In addition,
NIH recently released a statement on the sharing of
research data that applies to all investigator-initiated
applications with direct costs greater than $500,000 in
any single year (http://grants.nih.gov/grants/guide/
notice-ﬁles/NOT-OD-03-032.html).
All applicants who respond to this PAS must
propose plans for sharing data and biomaterials gen-
erated through the grant. Applicants should explain
how funds for the storage and distribution of data
and biomaterials will be obtained, and may request
such funds in the budget of the application. It is
expected that the data to be shared will be clinical,
diagnostic, and pedigree structure information, and
information about the genetic backgrounds and phe-
notypes of mutant or transgenic animal strains.
Biomaterials to be shared will include patient DNAs
and cell lines, and mutant or transgenic animal
strains. When possible, data and biomaterials should
be placed in databases or repositories that will permit
their efﬁcient distribution to investigators throughout
the scientiﬁc community. An example of such a facil-
ity is the NINDS Human Genetics Resource Center
(http://locus.umdnj.edu/ninds).
The Initial Review Group will evaluate the pro-
posed sharing plan and comment on its adequacy in
an administrative note in the summary statement.
Reviewers will not factor the proposed data-sharing
plan into the determination of scientiﬁc merit or pri-
ority score. The adequacy of the plan will be consid-
ered by NIH staff in determining whether the grant
shall be awarded. The sharing plan as approved, after
negotiation with the applicant when necessary, will
be a condition of the award.
Our understanding of pathogenic mechanisms
in VCI would beneﬁt tremendously from the use of
standardized criteria for diagnosing this condition,
including standardized methods for measuring cogni-
tive function. NINDS plans to encourage and coor-
dinate the use of a minimal diagnostic dataset in
studies funded by this PAS. Until such a dataset is
defined, applicants to this PAS should provide
detailed descriptions of the patient data to be col-
lected, including methods for independently assessing
the presence and type of cerebrovascular disease, and
levels of cognitive function. Rationale for choice of
speciﬁc cognitive test(s) should be included. In addi-
tion, plans should be included for entry of disease
and cognitive phenotypic data into a computerized
database that may be easily shared with other
researchers.
Applicants to be funded under this PAS will be
expected to travel to NIH once a year to share
progress with NIH program staff, other investigators
funded under this PAS, and additional advisers as
deemed necessary by NIH program staff. Applicants
should include funds to support one trip per year to
Bethesda, MD (for the principal investigator and co-
principal investigators only).
Applications must be prepared using the PHS
398 research grant application instructions and
forms (rev. 5/2001). Applications must have a Dun
and Bradstreet (D&B) Data Universal Numbering
System (DUNS) number as the Universal Identiﬁer
when applying for federal grants or cooperative
agreements. The D&B number can be obtained by
calling 866-705-5711 or through the web site at
http://www.dunandbradstreet.com/. The D&B
number should be entered on line 11 of the face
page of the PHS 398 form. The PHS 398 is available
at http://grants.nih.gov/grants/funding/phs398/
phs398.html in an interactive format. For further
assistance contact GrantsInfo, 301-435-0714, e-
mail: GrantsInfo@nih.gov. The title and number of
this PA must be typed on line 2 of the face page of
the application form and the YES box must be
checked.
Submit a signed, typewritten original of the
application, including the checklist, and ﬁve signed
photocopies in one package to: Center for Scientiﬁc
Review, National Institutes of Health (NIH), 6701
Rockledge Drive, Room 1040, MSC 7710, Bethesda,
MD 20892-7710 USA; Bethesda, MD 20817 (for
express/courier service).
Applications must be mailed on or before the
receipt dates described at http://grants.nih.gov/
grants/funding/submissionschedule.htm. The CSR
will not accept any application in response to this
PAS that is essentially the same as one currently
pending initial review unless the applicant withdraws
the pending application. The CSR will not accept
any application that is essentially the same as one
already reviewed. This does not preclude the submis-
sion of a substantial revision of an unfunded version
of an application already reviewed, but such applica-
tion must include an introduction addressing the
previous critique.
Contact: Gabrielle G. Leblanc, Program
Director, Neurogenetics, National Institute of
Neurological Disorders and Stroke (NINDS),
Neuroscience Center, Suite 2136, MSC 9537,
Bethesda, MD 20892-0001 USA, 301-496-5745,
fax: 301-402-1501; e-mail: leblancg@ninds.nih.gov;
Creighton H. Phelps, Director, Alzheimer's
Disease Centers Program, Neuroscience and
Neuropsychology of Aging, National Institute on
Aging (NIA), National Institutes of Health, 7201
Wisconsin Ave., Suite 350, Bethesda, MD, 20892-
0001 USA; 301-496-9350, fax: 301-496-1494; e-
mail: phelpsc@nia.nih.gov; Stephen S. Goldman,
Vascular Biology Research Program, Division of
Heart and Vascular Diseases, National Heart, Lung,
and Blood Institute (NHLBI), 6701 Rockledge
Drive, Suite 10192, MSC 7956, Bethesda, MD
20892-0001 USA, 301-435-0560, fax: 301-480-
2858, e-mail: goldmans@nhlbi.nih.gov.
Reference: PA No. PAS-04-149
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